Article

Proprotein Convertase Subtilisin/Kexin Type 9 in the Inflammation-Related Dyslipidemia of Patients with Axial Spondyloarthritis is Related to Disease Activity.

2020-04-07

Abstract excerpt

<title>Abstract</title> <p>Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation and that has been linked to cardiovascular risk. The purpose of the present study was to examine whether PCSK9 levels are related to both abnormalities in the lipid profile and the development of severe athero...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5c50784f-d0e8-52ba-b512-def1a7d2957a
DOI: 10.21203/rs.3.rs-21063/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Proprotein Convertase Subtilisin/Kexin Type 9 in the Inflammation-Related Dyslipidemia of Patients with Axial Spondyloarthritis is Related to Disease Activity.DOI 10.21203/rs.3.rs-21063/v1Read

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.Semantic proximity Read

PCSK9 inhibitors ameliorate arterial stiffness in ACS patients: evidences from mendelian randomization, cohort studies and basic experimentsSemantic proximity Read

Proprotein Convertase Subtilisin/kexin Type 9 Links Inflammation to Vascular Endothelial Cell DysfunctionSemantic proximity Read

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Semantic proximity Read

Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.Semantic proximity Read

Clinical aspects of PCSK9.Semantic proximity Read

Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).Semantic proximity Read

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular diseaseSemantic proximity Read

Impact of PCSK9 inhibitors on bone disease: A comprehensive drug-target Mendelian randomization studySemantic proximity Read

Meta-GWAS of PCSK9 levels detects two novel loci atAPOBandTM6SF2Semantic proximity Read

Omentin: a biomarker of cardiovascular risk in individuals with axial spondyloarthritis.Semantic proximity Read

The PCSK9 decade.Semantic proximity Read